论文部分内容阅读
目的分析白塞病患者心脏受累的临床特点。方法回顾性分析北京协和医院1990-2006年确诊的心脏受累的白塞病患者的临床资料。结果我院1990-2006年住院治疗的白塞病患者348例,有心脏受累的白塞病患者42例,占12.1%。心脏受累的表现主要有瓣膜病变(17例)、心绞痛(12例)、心包积液(10例)、心律失常(4例)、心腔血栓(5例)、肺动脉高压(10例)等。42例患者采用糖皮质激素治疗,33例用免疫抑制剂治疗,其他治疗还有动脉瘤患者置入带膜支架、主动脉换瓣、动脉瘤手术切除、下腔静脉血栓置网、右室血栓手术取栓等,手术换瓣或介入治疗的效果与全身白塞病的活动性有关。42例患者好转30例,占71.4%。恶化6例,占14.3%。住院死亡6例,占14.3%。logistic 回归分析显示,肺动脉受累是白塞病心脏损害患者死亡的独立相关因素(P=0.03)。结论白塞病累及心脏的表现多种多样;需要换瓣手术或者介入治疗者,应在白塞病非活动期进行;肺动脉受累是有心脏受累的白塞病患者死亡的独立危险因素。
Objective To analyze the clinical features of heart involvement in patients with Behcet’s disease. Methods The clinical data of Behcet’s patients with heart involvement diagnosed in Peking Union Medical College from 1990 to 2006 were retrospectively analyzed. Results 348 cases of Behcet’s disease hospitalized in our hospital from 1990 to 2006, 42 cases of Behcet’s disease with heart involvement, accounting for 12.1%. Cardiac involvement mainly includes valvular disease (17 cases), angina pectoris (12 cases), pericardial effusion (10 cases), arrhythmia (4 cases), cardiac thrombus (5 cases) and pulmonary hypertension (10 cases). Forty-two patients were treated with glucocorticoid, 33 patients were treated with immunosuppressive agents, and others were treated with stent-graft, aortic valve replacement, aneurysm resection, placement of inferior vena cava thrombus, right ventricular thrombus Surgical thrombectomy, etc., the effect of surgery for valve replacement or interventional treatment is related to the activity of systemic Behcet’s disease. 42 patients improved in 30 cases, accounting for 71.4%. 6 cases of deterioration, accounting for 14.3%. 6 died in hospital, accounting for 14.3%. Logistic regression analysis showed that pulmonary involvement was independently associated with death from Behcet’s heart injury (P = 0.03). Conclusions Behcet’s disease affects the heart in a variety of ways. Patients who require valve replacement or intervention should be treated during the inactive period of Behçet’s disease. Pulmonary artery involvement is an independent risk factor for the death of patients with Behcet’s disease.